ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Scheduled to Post Quarterly Earnings on Monday
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, July 31st. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Monday, May 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03. The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.71 million. The firm’s quarterly revenue was down 18.8% compared to the same quarter last year. On average, analysts expect ZIOPHARM Oncology to post $-0.58 EPS for the current fiscal year and $-0.64 EPS for the next fiscal year.
Shares of ZIOPHARM Oncology Inc (NASDAQ ZIOP) traded down 5.20% during midday trading on Thursday, hitting $5.65. The company’s stock had a trading volume of 1,321,354 shares. The company’s market cap is $738.46 million. The company has a 50-day moving average price of $5.92 and a 200 day moving average price of $6.35. ZIOPHARM Oncology Inc has a 1-year low of $4.55 and a 1-year high of $7.88.
A number of research analysts have recently issued reports on the company. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. HC Wainwright assumed coverage on ZIOPHARM Oncology in a research note on Thursday, June 1st. They issued a “buy” rating and a $9.50 price objective on the stock. Finally, Zacks Investment Research raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, April 26th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $13.00.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.